Latest Healthcare News

Pro Medicus' U.S. subsidiary Visage Imaging has extended its contract with The Ohio State University Wexner Medical Center for five years, adding new Visage 7 modules and increasing transaction fees, underpinning strong client retention and platform demand.

Biome Australia has inked a binding deal with Specialty Probiotics Australia to shift its Activated Probiotics manufacturing onshore, aiming to boost gross margins above 65% and streamline working capital within 18 months.

Pacific Edge has secured NZ$36.1 million through a combination of a NZ$25.4 million placement and a significantly oversubscribed retail offer, reinforcing its strategic position to expand the Cxbladder cancer diagnostic platform.

Promisia Healthcare reported a 58% jump in underlying EBITDAF to $6.6 million for FY26, driven by improved occupancy and operational upgrades. The company introduced a dividend policy tied to operating free cash flow, signalling confidence in sustained cash generation.

ImpediMed has revamped its leadership with two new commercial roles and reported encouraging sales momentum for its SOZO device. The company is advancing clinical trials and expanding its presence in cancer survivorship, weight management, and heart health sectors.

Vitrafy Life Sciences has teamed up with Vitalant Innovation Center to tackle the impending gap in red blood cell cryopreservation technology in the US, aiming to replace soon-to-be-discontinued legacy methods and potentially expand into other blood products.

Imagion Biosystems has secured FDA clearance to proceed with its Phase 1b/2 trial of the MagSense® HER2 Imaging Agent, targeting improved detection of HER2+ breast cancer. Patient recruitment is expected to start in Q3 2026, marking a crucial step toward commercialisation.

Stakk Ltd has secured a significant U.S. healthcare technology contract, pushing its annualised revenue run rate to approximately A$26 million. The deal highlights accelerating adoption of its AI-native Digital Trust platform across regulated industries.

Green Cross Health plans to sell its Medical division, The Doctors, for NZ$270 million to Tend Health, refocusing on its pharmacy business. Completion hinges on shareholder approval expected by July 2026.

Intelligent Monitoring Group (ASX:IMB) has finalized its A$37 million purchase of Wormald NZ and Red Wolf, expanding its New Zealand footprint and projecting a 20.9% accretion in earnings per share.

Optiscan and Mayo Clinic have completed all key engineering milestones in their two-year partnership to develop a digital endomicroscopic imaging system for robotic surgery, extending their agreement to support further clinical and commercial planning.

ReNerve has inked an exclusive three-year deal with Hong Kong’s Swedish Trading Company to distribute its nerve repair products across a vast and dynamic healthcare region.